Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria
The landmark study only includes small number of these patients who undergo PCI, raising questions about the data and its relation to real-world practice
Getty Images
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for stable ischemic heart disease (SIHD) in the U.S. did not meet enrollment criteria for the ISCHEMIA trial. The data, which was presented as a late-breaking study at the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 virtual meeting, demonstrates that only a minority of SIHD patients referred for coronary intervention in contemporary practice clearly resemble those enrolled in the ISCHEMIA trial.
April 30, 2021
Research compares the ISCHEMIA trial enrollment criteria to real-world interventional practice in the U.S.
WASHINGTON, D.C. (APRIL 30, 2021) – Results from a new study find a broad range of patients who typically undergo revascularization for stable ischemic heart disease (SIHD) in the U.S. did not meet enrollment criteria for the ISCHEMIA trial. The data, which was presented April 29th as late-breaking clinical science at the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 Virtual Scientific Sessions, demonstrates that a minority of SIHD patients referred for coronary intervention in contemporary practice clearly resemble those enrolled in the ISCHEMIA trial
Ischemic heart disease impacts more than 13 million people in the United States and is the leading cause of death and disability worldwide. Treatment for ischemia includes a variety of medical therapies as well as procedures like percutaneous coronary intervention (PCI) to open up clogge
April 30, 2021
A second-generation robotic PCI system improves both clinical and technical success over its predecessor and shows the potential to positively impact operators’ health and quality of life, according to data from the PRECISION GRX study.
“[I]f you work in the cath lab for more than 15 years, you have significant occupational hazards, both orthopedic related, as well as associated with radiation,” said Ehtisham Mahmud, MD (University of California, San Diego), in his presentation yesterday at the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 Scientific Sessions. Mahmud said data from the PRECISE and RAPID studies indicate that operators who sit at a cockpit without their lead and conduct PCI robotically for either coronary or peripheral interventions can reduce their radiation exposure by as much as 95%. However, while first-generation systems were demonstrated to
April 29, 2021
Since the approval of TAVI for the treatment of symptomatic severe aortic stenosis more than a decade ago, the overwhelming number of new TAVI programs have been launched in metropolitan areas, according to a new study presented today. Moreover, more than half of these programs were launched in cities where TAVI was already available at another nearby center.
The findings, said lead investigator Ashwin Nathan, MD (Hospital of the University of Pennsylvania, Philadelphia), highlight the disparities in access to new advances in cardiovascular medicine.
“The increased number of TAVR programs over the last 10 years has not necessarily translated to increased access,” said Nathan. “TAVR sites are predominantly located in metropolitan areas, and the majority of TAVR sites, when they open, open in areas with a preexisting program. This increase numerically does not necessarily translate into increased geographic access.”
E-Mail
WASHINGTON, D.C. (APRIL 29, 2021) - Results from a new study find a broad range of patients who typically undergo revascularization for stable ischemic heart disease (SIHD) in the U.S. did not meet enrollment criteria for the ISCHEMIA trial. The data, which was presented today as late-breaking clinical science at the Society for Cardiovascular Angiography & Interventions (SCAI) 2021 Scientific Sessions, demonstrates a minority of SIHD patients referred for coronary intervention in contemporary practice clearly resemble those enrolled in the ISCHEMIA trial.
Ischemic heart disease impacts more than 13 million people in the United States and is the leading cause of death and disability worldwide. Treatment for ischemia includes a variety of medical therapies as well as procedures like percutaneous coronary intervention (PCI) to open up clogged arteries and improve blood flow to the heart. The 2020 ISCHEMIA trial, which found the procedure strategy did not decrease the risk o